130 related articles for article (PubMed ID: 1397246)
21. Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma.
Avvisati G; Petrucci MT; Pulsoni A; Tribalto M; Lauta VM; Gernone A; Boccadoro M; Marmont F; Pileri A; Dammacco F
Eur J Haematol Suppl; 1990; 52():9-11. PubMed ID: 2279547
[No Abstract] [Full Text] [Related]
22. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma.
Kars A; Celik I; Kansu E; Tekuzman G; Ozişik Y; Güler N; Barişta I; Güllü I; Yalçin S; Altundağ K; Zengin N; Türker A; Hayran M; Baltali E; Firat D
Eur J Haematol; 1997 Aug; 59(2):100-4. PubMed ID: 9293857
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma.
Alexanian R; Weber D; Dimopoulos M; Delasalle K; Smith TL
Am J Hematol; 2000 Nov; 65(3):204-9. PubMed ID: 11074536
[TBL] [Abstract][Full Text] [Related]
24. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
[TBL] [Abstract][Full Text] [Related]
25. A review of the clinical studies of alpha-interferon in the management of multiple myeloma.
Cooper MR
Semin Oncol; 1991 Oct; 18(5 Suppl 7):18-29. PubMed ID: 1948125
[TBL] [Abstract][Full Text] [Related]
26. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.
Shustik C; Belch A; Robinson S; Rubin SH; Dolan SP; Kovacs MJ; Grewal KS; Walde D; Barr R; Wilson J; Gill K; Vickars L; Rudinskas L; Sicheri DA; Wilson K; Djurfeldt M; Shepherd LE; Ding K; Meyer RM
Br J Haematol; 2007 Jan; 136(2):203-11. PubMed ID: 17233817
[TBL] [Abstract][Full Text] [Related]
27. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
[TBL] [Abstract][Full Text] [Related]
28. A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.
Hübel K; Tesch H; Kröger B; Schnell R; Borchmann P; Diehl V; Engert A
Leukemia; 1997 Dec; 11 Suppl 5():S47-51. PubMed ID: 9436939
[TBL] [Abstract][Full Text] [Related]
29. Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial.
Offidani M; Olivieri A; Montillo M; Rupoli S; Centurioni R; Alesiani F; Marchegiani G; Pieroni S; Catarini M; Pelliccia G; Altilia F; Leoni P
Haematologica; 1998 Jan; 83(1):40-7. PubMed ID: 9542322
[TBL] [Abstract][Full Text] [Related]
30. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.
Avilés A; Neri N; Huerta-Guzmán J; Pérez F; Sotelo L
Leuk Lymphoma; 2004 Nov; 45(11):2247-51. PubMed ID: 15512813
[TBL] [Abstract][Full Text] [Related]
31. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan.
Wada M; Mizoguchi H; Kuriya SI; Taguchi H; Kawamura T; Maekawa I; Shimazaki C; Sato Y; Niho Y; Miyazaki T; Shibata A; Kitani T; Hamajima N; Ohno R
Br J Haematol; 2000 Jun; 109(4):805-14. PubMed ID: 10929034
[TBL] [Abstract][Full Text] [Related]
32. Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.
Joshua DE; Penny R; Matthews JP; Laidlaw CR; Gibson J; Bradstock K; Wolf M; Goldstein D
Br J Haematol; 1997 Apr; 97(1):38-45. PubMed ID: 9136940
[TBL] [Abstract][Full Text] [Related]
33. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
[TBL] [Abstract][Full Text] [Related]
34. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
[TBL] [Abstract][Full Text] [Related]
35. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
36. [Alpha-2a-interferon (Reaferon) in the treatment of patients with multiple myeloma].
Bessmel'tsev SS; Abdulkadyrov KM
Vopr Onkol; 1999; 45(4):393-7. PubMed ID: 10532098
[TBL] [Abstract][Full Text] [Related]
37. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
Wisløff F; Hjorth M; Kaasa S; Westin J
Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893
[TBL] [Abstract][Full Text] [Related]
38. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
Aviles A; Duque G; Talavera A; Guzman R
Leuk Lymphoma; 1996 Feb; 20(5-6):495-9. PubMed ID: 8833409
[TBL] [Abstract][Full Text] [Related]
39. [The polychemotherapy of patients with multiple myeloma].
Abdulkadyrov KM; Bessmel'tsev SS
Vopr Onkol; 1992; 38(3):345-51. PubMed ID: 1300725
[TBL] [Abstract][Full Text] [Related]
40. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
